Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Several months later, in February 1997, the corporation acquired Rockwell Medical Supplies and Rockwell Transportation, and Chioini remained president and CEO of the reorganized company.
More importantly Rockwell improved its prospects further in June 1997 when it received 510(k) approval from the Food and Drug Administration (FDA) to market a dry power that could be converted into liquid form on site.
In 1997 Rockwell generated $3.3 million in sales and posted a net loss of $1.9 million.
Rockwell outgrew the capabilities of its Michigan plant and in 2000 took steps to add capacity by leasing a 51,000-square-foot manufacturing facility in Grapevine, Texas, near Dallas.
Furthermore, Rockwell added a major customer in 2002, Nashville-based National Nephrology Associates, Inc., the country’s sixth largest provider of dialysis services.
Lewis appealed the decision, and finally in the first quarter of 2005 the two parties agreed to a settlement price of approximately $241,000.
In the early weeks of 2005 Rockwell signed a series of contracts that added significantly to its roster of customers, especially in the mid-Atlantic and south Atlantic states.
In May 2006, it added the country’s fourth largest provider of dialysis services, Brentwood, Tennessee-based Renal Advantage Inc., as a customer.
Rockwell continued to position itself for future growth on a number of fronts in 2006.
"Rockwell Medical Technologies, Inc. ." International Directory of Company Histories. . Retrieved June 22, 2022 from Encyclopedia.com: https://www.encyclopedia.com/books/politics-and-business-magazines/rockwell-medical-technologies-inc
Rate Rockwell Medical's efforts to communicate its history to employees.
Do you work at Rockwell Medical?
Is Rockwell Medical's vision a big part of strategic planning?
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Med Immune Inc | 1988 | $1.7B | 5,000 | - |
| Cubist Pharmaceuticals | 1992 | $926.4M | 873 | - |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 275 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 845 |
| Merck | 1891 | $64.2B | 74,000 | 1,485 |
| Zoetis | 1952 | $9.3B | 11,300 | 221 |
| Seagen | 1997 | $2.0B | 900 | - |
| Ligand Pharmaceuticals | 1987 | $241.5M | 116 | - |
| Emergent BioSolutions | 1998 | $1.6B | 1,834 | 3 |
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 22 |
Zippia gives an in-depth look into the details of Rockwell Medical, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Rockwell Medical. The employee data is based on information from people who have self-reported their past or current employments at Rockwell Medical. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Rockwell Medical. The data presented on this page does not represent the view of Rockwell Medical and its employees or that of Zippia.
Rockwell Medical may also be known as or be related to ROCKWELL MEDICAL Inc, ROCKWELL MEDICAL, INC., Rockwell Medical, Rockwell Medical Inc, Rockwell Medical Inc. and Rockwell Medical, Inc.